Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Ocugen

< Previous 1 2 3 4 Next >
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Present at Investing in Cures Summit
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Clinical Showcase Webcast Now Available
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Present at 2024 BIO CEO & Investor Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Present at Pharma Market Research Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.